|
市場調査レポート
商品コード
1115332
非ステロイド性抗炎症薬の世界市場規模、シェア、産業動向分析レポート:投与経路別、流通チャネル別、適応症別、地域別展望と予測、2022年~2028年Global Non-steroidal Anti-inflammatory Drugs Market Size, Share & Industry Trends Analysis Report By Route of Administration, By Distribution Channel, By Route of Disease Indication, By Regional Outlook and Forecast, 2022 - 2028 |
||||||
非ステロイド性抗炎症薬の世界市場規模、シェア、産業動向分析レポート:投与経路別、流通チャネル別、適応症別、地域別展望と予測、2022年~2028年 |
出版日: 2022年07月29日
発行: KBV Research
ページ情報: 英文 225 Pages
納期: 即納可能
|
非ステロイド性抗炎症薬の世界市場規模は、2028年までに255億米ドルに達し、予測期間中にCAGR5.7%の市場成長率で上昇すると予測されています。
予測期間中、慢性疼痛の有病率は増加すると予想され、NSAID市場の成長を促進しています。例えば、CDCは、米国では2019年に成人の約20,4%が慢性疼痛を経験したと推定しています。慢性疼痛の有病率における年齢による増加は、65歳以上で最も顕著に見られます。ヒスパニック系、非ヒスパニック系アジア人、非ヒスパニック系黒人と比較して、非ヒスパニック系白人の慢性疼痛の有病率が最も高かったです。非ヒスパニック系白人の成人の約23.6%が慢性的な不快感に悩まされています。したがって、COX-2選択的および非選択的NSAIDsの両方が慢性疼痛の管理に頻繁に採用されていることを考えると、慢性疼痛の有病率の増加が成長を促進すると予想されます。
COVID-19の影響分析
感染症COVID-19は、12月下旬に中国湖北省の武漢市で初めて表面化しました。SARS-CoV-2という急性呼吸器症候群を引き起こすウイルスは、非常に感染力が強く、人から人へと広がっていく。2019年12月の発生以来、ウイルスは213カ国に広がり、世界保健機関はパンデミック(世界的流行病)に分類しています。COVID-19の発生に対して、世界各国の政府や製薬・バイオテクノロジー企業は、医療サプライチェーンの管理から予防接種の作成支援に至るまで、共同で取り組んでいます。その結果、COVID-19ワクチン接種とその治療薬に対する需要が、製薬およびバイオテクノロジー分野を前進させると予測されています。
市場成長要因
慢性疼痛の発生率の増加
薬物療法や治療なしに12週間以上続く痛みは、慢性痛または持続性痛と呼ばれます。怪我や手術による痛みから回復し、元通りになる人もいます。しかし、事故や手術の前歴がなくても、痛みが長く続いたり、突然痛みが現れたりすることがあります。非ステロイド性抗炎症薬の市場拡大の主な要因の1つは、痛みや炎症を引き起こす疾患の有病率が上昇していることです。これらの薬剤は、急性および慢性の痛みの治療に頻繁に使用されています。イブプロフェン&ジクロフェナクは、頻繁に痛みを治療するために推奨されている2つの薬です。
オピオイドよりNSAIDを好む人が増えています。
軽度から重度の疼痛管理に最もよく使用されるのは、非ステロイド性抗炎症薬とオピオイドです。しかし、オピオイドの使用は、深刻な有害事象と関連しています。数千年前の文明の夜明け以来、オピオイドは痛みを和らげるために使用されてきました。オピオイド鎮痛薬は、鈍い痛み、局所的でない痛み、典型的には腹痛の治療に頻繁に使用されます。頻繁に服用すると薬物耐性と依存性が生じ、オピオイド鎮痛剤を突然止めると禁断症状を引き起こす可能性があります。オピオイドを含まない非ステロイド性抗炎症薬(NSAIDs)は、疼痛管理のために最も頻繁に処方される鎮痛剤です。これらの医薬品は、大量に服用することで、解熱、鎮痛、抗炎症作用も発揮します。
市場抑制要因
Nsaidsの副作用による消費量の制限
アレルギー反応、胃痛、胃潰瘍、めまいなど、NSAIDの使用による副作用が市場の成長を抑制すると予想されます。NSAIDは、その入手のしやすさと抗炎症作用から、最も多く処方される医薬品の一つです。しかし、NSAIDに関連する消化器系の問題は世界的に著しく増加しており、ヘルスケアシステムに負担をかける可能性があります。緊急入院の最も多い理由は、NSAIDsに関連する消化管出血です。さらに、その副作用は、米国で最も典型的な薬物副作用となっています。
疾患別適応症の展望
非ステロイド性抗炎症薬市場は、適応症に基づき、関節炎、偏頭痛、眼科疾患、その他に区分されます。2021年の非ステロイド性抗炎症薬市場では、関節炎セグメントが最も高い収益シェアを獲得しました。関節炎および変形性関節症の全体的な発生率、世界の高齢者人口の増加、NSAIDsの強い処方率、局所関節炎治療薬の人気の上昇などが、このセグメントの成長の要因となっています。
投与経路の展望
非ステロイド性抗炎症薬市場は、投与経路別に、経口剤、局所剤、その他に分類されます。2021年の非ステロイド性抗炎症薬市場では、経口セグメントが最大の収益シェアを獲得しています。これは、痛み、頭痛、発熱、片頭痛の治療に利用できる経口NSAIDsが豊富なことと、OTC NSAIDの売上が増加しているためです。頭痛や偏頭痛を治療するために、ジョンソン・エンド・ジョンソンコンシューマーインクは、NSAID薬のモトリン(イブプロフェン)を提供しており、タブレット、液体ゲル、カプセル、溶液などの投与形態で提供されています。
流通経路の展望
非ステロイド性抗炎症薬市場は、流通チャネル別に病院薬局、小売薬局、オンライン薬局に分類されます。病院薬局セグメントは、2021年の非ステロイド性抗炎症薬市場で大きな収益シェアを獲得しました。それは、非ステロイド性抗炎症薬が入院患者の痛みを治療するために広く使用されているためです。それとともに、世界各国の病院数の増加が、予測期間中の同分野の成長をエスカレートさせるでしょう。
地域別の展望
地域別に見ると、非ステロイド性抗炎症薬市場は、北米、欧州、アジア太平洋およびLAMEAで分析されています。北米は、2021年に最大の収益シェアを獲得し、非ステロイド性抗炎症薬市場の主要地域として浮上しました。市場の成長に影響を与える重要な変数には、相当数のメーカーの存在や、業界参加者による戦略的行動などがあります。また、予測期間中に関節炎や慢性疼痛の有病率が上昇し、成長が加速することが予測されています。
List of Figures
The Global Non-Steroidal Anti-inflammatory Drugs Market size is expected to reach $25.5 billion by 2028, rising at a market growth of 5.7% CAGR during the forecast period.
Non-steroidal anti-inflammatory medications (NSAIDs) are used to alleviate pain, lower fevers, and improve blood circulation. Furthermore, the inflammation is decreased when high dosages of non-steroidal anti-inflammatory medicines (NSAIDs) are given. Non-steroidal medications have sedative and anti-inflammatory effects. Inflammation is caused by the COX-1 and COX-2 enzymes that are inhibited by non-steroidal anti-inflammatory medications (NSAIDs). Aspirin, naproxen, ibuprofen, and paracetamol are examples of typical non-steroidal anti-inflammatory medications.
The market for non-steroidal anti-inflammatory medications (NSAIDs) is expanding as a result of a number of causes, including the growing incidence of chronic pain worldwide and an ageing population. The expanding use of NSAIDs for headache, toothache, migraine, and menstrual pain, as well as growing preference for OTC NSAIDs, are also anticipated to contribute to the growth over the forecast period. Additionally, the accessibility of a wide range of NSAID products as well as an increase in product approvals and launches are projected to fuel growth over the forecast period.
During the projected period, the prevalence of chronic pain is anticipated to increase, driving NSAID market growth. For instance, the CDC estimates that in the United States, about 20,4% of adults experienced chronic pain in 2019. Age-related increases in the prevalence of chronic pain were most pronounced in persons 65 years of age and older. Compared to Hispanic, non-Hispanic Asian, and non-Hispanic black individuals, non-Hispanic whites had the highest prevalence of chronic pain. About 23.6 percent of non-Hispanic white adults suffer from chronic discomfort. Therefore, given that both COX-2 selective and non-selective NSAIDs are frequently employed in the management of chronic pain, the increasing prevalence of chronic pain is anticipated to promote growth.
COVID-19 Impact Analysis
The infectious disease COVID-19 first surfaced in late December in the Chinese city of Wuhan's Hubei province. SARS-CoV-2, the virus that causes the acute respiratory syndrome is extremely contagious and spreads from person to person. The virus has spread to 213 nations since its outbreak in December 2019, prompting the World Health Organization to classify it as a pandemic. Governments and pharmaceutical and biotech businesses from all around the world are collaborating to combat the COVID-19 outbreak, from managing the medical supply chain to assisting in the creation of vaccinations. As a result, the demand for the COVID-19 vaccination and its treatment medications is predicted to propel the pharmaceutical and biotechnology sectors forward.
Market Growth Factors
Growing Incidence Of Chronic Pain
Pain that persists for more than 12 weeks without medication or treatment is referred to as chronic or persistent pain. Several people recover from pain due to injuries or operation and return to normalcy. However, there are situations when the pain lasts longer or appears suddenly without any prior history of an accident or surgery. One of the key factors propelling the market expansion for non-steroidal anti-inflammatory medications is the rising prevalence of disorders that cause pain and inflammation. These medications are being used more frequently to treat both acute & chronic pain. Ibuprofen & diclofenac are two medications that are frequently recommended to treat pain.
Increasing Preference Of People For Nsaids Over Opioids
The most often recommended medications for the management of mild to severe pain are NSAIDs and opioids. Opioid use, however, is linked to serious adverse outcomes. Since the dawn of civilization thousands of years ago, opioids have been used to relieve pain. Opioid analgesics are frequently used to treat dull, ill-localized pain, typically abdominal pain. Frequent doses may result in drug tolerance and dependency, and abruptly stopping an opioid painkiller may trigger a withdrawal crisis. Non-opioid, non-steroidal anti-inflammatory medicines (NSAIDs), which do not include opioids, are the most often prescribed analgesics for the management of pain. At larger doses, these medications also have antipyretic, analgesics, and anti-inflammatory properties.
Market Restraining Factors
Adverse Effects Of Nsaids Would Restrict Its Consumption
The market growth is anticipated to be constrained by adverse reactions to NSAID use, including allergic reactions, stomach pain, stomach ulcers, and dizziness. These pharmaceuticals are one of the most often prescribed medicines due to their widespread accessibility and anti-inflammatory effects. However, NSAID-related gastrointestinal issues are on the rise significantly globally, which could put a strain on the healthcare system. The most frequent reason for the most of emergency hospital admissions is GI bleeding related to NSAIDs. Additionally, its side effect is the most typical drug side in the United States.
Disease Indication Outlook
Based on disease indication, the Non-steroidal Anti-inflammatory Drugs Market is segmented into Arthritis, Migraine, Ophthalmic Diseases and Others. The arthritis segment acquired the highest revenue share in the Non-steroidal Anti-inflammatory Drugs Market in 2021. The overall incidence of arthritis & osteoarthritis, the growing senior population worldwide, the strong prescription rate for NSAIDs, and the rise in popularity of topical arthritis treatments are all contributing factors to the segment's growth.
Route of Administration Outlook
By Route of Administration, the Non-steroidal Anti-inflammatory Drugs Market is classified into Oral, Topical and Others. The oral segment garnered the maximum revenue share in the Non-steroidal Anti-inflammatory Drugs Market in 2021. It is due to the abundance of oral NSAIDs available for treating pain, headaches, fever, and migraines as well as the rise in OTC NSAID sales. To treat headaches and migraines, Johnson & Johnson Consumer Inc. provides their NSAID medication Motrin (ibuprofen), which is offered in dose forms such a tablet, liquid gel, capsule, and solution.
Distribution Channel Outlook
On the basis of distribution channel, the Non-steroidal Anti-inflammatory Drugs Market is divided into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. The hospital pharmacy segment acquired a significant revenue share in the Non-steroidal Anti-inflammatory Drugs Market in 2021. It is because non-steroidal anti-inflammatory medications are widely used to treat pain in hospitalized patients. Along with that, the rise in the number of hospitals across various nations of the world would escalate the growth of the segment over the forecast period.
Regional Outlook
Region-wise, the Non-steroidal Anti-inflammatory Drugs Market is analyzed across North America, Europe, Asia Pacific and LAMEA. North America emerged as the leading region in the Non-steroidal Anti-inflammatory Drugs Market with the maximum revenue share in 2021. Some of the key variables influencing the market's growth include the existence of a sizable number of manufacturers and the strategic actions made by industry participants. In addition, it is predicted that the prevalence of arthritis and chronic pain will rise during the forecast period, accelerating growth.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Dr. Reddy's Laboratories Ltd., Pfizer, Inc., GlaxoSmithKline PLC, Bayer AG, Teva Pharmaceuticals Industries Ltd., Eli Lilly And Company, Sanofi S.A., AstraZeneca PLC, Viatris, Inc., and Merck & Co., Inc.
Recent Strategies deployed in Non-steroidal Anti-inflammatory Drugs Market
Partnerships, Collaborations and Agreements:
May-2022: Dr. Reddy's Laboratories formed a partnership with South Korea-based HK inno.N Corporation. Through this partnership, Tegoprazan would offer a new option for the treatment of gastric acid-related as well as mobility-impaired diseases like Erosive/Non-erosive Gastroesophageal Reflux Disease (GERD / NERD), Nonsteroidal anti-inflammatory drug-mediated ulcers, Gastric and Duodenal ulcers, and Helicobacter pylori eradication.
Product Launches and Product Expansions:
Aug-2021: Dr Reddy's Laboratories introduced over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg, the store-brand equivalent of Aleve, in the US market. This tablet is an over-the-counter non-steroidal anti-inflammatory drug (NSAID) for usage as a pain reliever and fever reducer.
May-2022: Dr. Reddy's Laboratories released Ketorolac Tromethamine Tablets USP, 10 mg, a therapeutic generic equivalent of the reference listed drug Toradol Tablets, 10 mg in the U.S. market. This product is a nonsteroidal anti-inflammatory drug (NSAID) demonstrated for the short-term management of moderately serious acute pain, which offers analgesia at the opioid stage and only as continuation treatment after intravenous or intramuscular dosing of ketorolac tromethamine, if necessary.
Approvals and Trails:
Feb-2022: Bayer received approval for Kerendia in the EU for adult people with chronic kidney disease related to type 2 diabetes. Kerendia is non-steroidal, which is a selective mineralocorticoid receptor (MR) antagonist to demonstrate positive kidney and cardiovascular (CV) results.
Jan-2022: Pfizer received approval from the United States (U.S.) Food and Drug Administration (FDA) for CIBINQO, an oral, once-daily, Janus kinase 1 (JAK1) inhibitor. CIBINQO is recommended for doses of 100 mg and 200 mg, along with the 200 mg dose being recommended for people for whom the medicine of 100 mg dose is less effective.
Dec-2020: GlaxoSmithKline got approval for BENLYSTA from the US Food and Drug Administration (FDA). This product is launched for the treatment of adult patients with active lupus nephritis (LN) who are getting standard therapy.
Sep-2020: Pfizer got the approval for XELJANZ from the United States (U.S.) Food and Drug Administration (FDA). This product is for the treatment of children and adolescents 2 years and elder with active polyarticular course juvenile idiopathic arthritis (pcJIA). In addition, the approval would make XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of pcJIA.
Mar-2020: GlaxoSmithKline received approval from the U.S. Food and Drug Administration (FDA) for Advil Dual Action with Acetaminophen as an over-the-counter (OTC) product for pain relief. This product would offer relief for various symptoms and is the first formulation, which integrates ibuprofen and acetaminophen, two powerful ingredients related to OTC pain relief that would work in multiple ways.
Feb-2020: GlaxoSmithKline got approval from the U.S. Food and Drug Administration (FDA) for Voltaren Arthritis Pain (diclofenac sodium topical gel, 1% (NSAID)- arthritis pain reliever). This product is an over-the-counter (OTC) product for the temporary relief of arthritis pain in the hand, elbow, wrist, ankle foot, or knee in adults.
Market Segments covered in the Report:
By Route of Administration
By Distribution Channel
By Disease Indication
By Geography
Companies Profiled
Unique Offerings from KBV Research